Autobahn’s elunetirom receives FDA fast track designation to treat adjunctive bipolar
Autobahn expects topline data from the ongoing Phase II AMPLIFY-BD trial in adjunctive bipolar depression in the second quarter of 2026.
Drug Development
SK bioscience and VECOL partner on Colombia vaccine manufacturing initiative
Thinning revenues: inside the $14bn Eliquis patent cliff
Next-generation platforms poised to redefine crowded HAE landscape
Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC
AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC
Gilead Sciences completes Tubulis acquisition for $5bn
Concept Life Sciences and OpenBench partner on drug discovery services
